Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, “window-of-opportunity” study
Neuro-Oncology · 02.06.2023 · 25 (6) · 1113-1122
DOI: 10.1093/neuonc/noac263 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Neuro-Oncology, online erschienen am 01.12.2022. Verfasst von Victor Moreno und 15 weiteren Autor:innen. Beteiligte Einrichtung: START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. Hauptthemen laut MEDLINE: Glioma, Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Celgene.
Abstract (Originalsprache)
Background
The bromodomain and extraterminal protein (BET) inhibitor trotabresib has demonstrated antitumor activity in patients with advanced solid tumors, including high-grade gliomas. CC-90010-GBM-001 (NCT04047303) is a phase I study investigating the pharmacokinetics, pharmacodynamics, and CNS penetration of trotabresib in patients with recurrent high-grade gliomas scheduled for salvage resection.
Methods
Patients received trotabresib 30 mg/day on days 1–4 before surgery, followed by maintenance trotabresib 45 mg/day 4 days on/24 days off after surgery. Primary endpoints were plasma pharmacokinetics and trotabresib concentrations in resected tissue. Secondary and exploratory endpoints included safety, pharmacodynamics, and antitumor activity.
Results
Twenty patients received preoperative trotabresib and underwent resection with no delays or cancelations of surgery; 16 patients received maintenance trotabresib after recovery from surgery. Trotabresib plasma pharmacokinetics were consistent with previous data. Mean trotabresib brain tumor tissue:plasma ratio was 0.84 (estimated unbound partition coefficient [KPUU] 0.37), and modulation of pharmacodynamic markers was observed in blood and brain tumor tissue. Trotabresib was well tolerated; the most frequent grade 3/4 treatment-related adverse event during maintenance treatment was thrombocytopenia (5/16 patients). Six-month progression-free survival was 12%. Two patients remain on treatment with stable disease at cycles 25 and 30.
Conclusions
Trotabresib penetrates the blood–brain-tumor barrier in patients with recurrent high-grade glioma and demonstrates target engagement in resected tumor tissue. Plasma pharmacokinetics, blood pharmacodynamics, and safety were comparable with previous results for trotabresib in patients with advanced solid tumors. Investigation of adjuvant trotabresib + temozolomide and concomitant trotabresib + temozolomide + radiotherapy in patients with newly diagnosed glioblastoma is ongoing (NCT04324840).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
- Department of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Bristol Myers Squibb, Princeton, New Jersey, USA.
- Bristol Myers Squibb, San Francisco, California, USA.
- Centre for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain.
ORCID-Profile: Victor Moreno, Juan Manuel Sepúlveda, Ángel Pérez-Núñez, Michael A Vogelbaum
Förderung
- Celgene
Zitieren
APA
Moreno, V., Manuel Sepúlveda, J., Reardon, D. A., Pérez-Núñez, Á., González León, P., Hanna, B., Filvaroff, E., Aronchik, I., Chang, H., Amoroso, B., Zuraek, M., Sanchez-Perez, T., Mendez, C., Stephens, D., Nikolova, Z., & Vogelbaum, M. A. (2023). Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, “window-of-opportunity” study. Neuro-Oncology, 25(6), 1113-1122. https://doi.org/10.1093/neuonc/noac263
Vancouver
Moreno V, Manuel Sepúlveda J, Reardon DA, Pérez-Núñez Á, González León P, Hanna B, et al. Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, “window-of-opportunity” study. Neuro-Oncology. 2023;25(6):1113-1122. doi:10.1093/neuonc/noac263
BibTeX
@article{Moreno2023,
author = {Moreno, Victor and Manuel Sepúlveda, Juan and Reardon, David A and Pérez-Núñez, Ángel and González León, Pedro and Hanna, Bishoy and Filvaroff, Ellen and Aronchik, Ida and Chang, Henry and Amoroso, Barbara and Zuraek, Marlene and Sanchez-Perez, Tania and Mendez, Cristina and Stephens, Daniel and Nikolova, Zariana and Vogelbaum, Michael A},
title = {Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, “window-of-opportunity” study},
journal = {Neuro-Oncology},
year = {2023},
volume = {25},
number = {6},
pages = {1113--1122},
doi = {10.1093/neuonc/noac263}
}
EUVIMED